ArticleJournal of animal science and biotechnology2026
Quercetin ameliorates aflatoxin B
Article in Journal of animal science and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAflatoxin B
methods4D Fast DIA-based micro-scale quantitative proteomics was conducted to identify the target proteins, and then immunofluorescence, qPCR, and parallel reaction monitoring (PRM) were conducted for the expression validation of the target proteins, and a series of analyses combined with the inhibitor experiments were conducted for the functional validation of the target proteins, including assessments of mitochondrial function (membrane potential ΔΨm, distribution, ATP levels), mitochondrial morphology observation by transmission electron microscopy (TEM), lipid peroxidation detection (LPO imaging, ROS and GSH detection), Fe
resultsOPA1 and ACSL4 are screened as the target proteins by micro-scale quantitative proteomics analysis, and immunofluorescence, qPCR and PRM validate their expression. Molecular docking reveals that there is an interaction of OPA1 and ACSL4, and QT exhibits stronger binding affinity to both OPA1 and ACSL4 than AFB
conclusionsQT alleviates AFB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.